<p>美國市場在過去一週保持平穩，但在過去 12 個月中上漲了 30%，預計年收益增長將達到 16%。在這種強勁的增長潛力背景下，識別高增長科技股需要關注那些展現出強大創新能力和適應能力的公司，以便抓住新興機會。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.35%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.05%</td>
<td>27.75%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>34.05%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>54.35%</td>
<td>95.02%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.25%</td>
<td>46.50%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 67 只股票的完整列表。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>Gyre Therapeutics (GYRE)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制藥公司，專注於開發和商業化用於治療器官纖維化的小分子藥物，市值為 6.7938 億美元。</p>
<p><strong>運營：</strong> Gyre Therapeutics 專注於開發和商業化針對器官纖維化的小分子藥物，主要通過其製藥部門產生收入，該部門報告收入為 1.1659 億美元。</p>
<p>儘管 Gyre Therapeutics 經歷了一個充滿挑戰的年份，盈利下降 58.4%，但它仍然是生物技術領域創新的燈塔。該公司的收入增長預計為每年 20.5%，超過美國市場平均水平 11%，反映出強勁的基本商業動態。最近，Gyre 在監管進展方面取得了重大進展；其主要產品候選 Hydronidone 在中國獲得了優先審查狀態，用於治療慢性乙型肝炎引起的肝纖維化，突顯其對全球健康結果的潛在影響。此外，Gyre 與 Cullgen 的戰略合併旨在增強其研究能力和市場覆蓋，承諾在競爭壓力和利潤波動中實現強勁的未來增長前景。</p>
<ul>
<li>通過閲讀我們的健康報告，深入瞭解 Gyre Therapeutics 的表現。</li>
<li>查看 Gyre Therapeutics 的過去表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 4 月的 GYRE 收入和支出明細</p>
<h2>Savara (SVRA)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Savara Inc.是一家臨牀階段生物製藥公司，致力於開發針對美國罕見呼吸疾病的治療，市值為 13 億美元。</p>
<p><strong>運營：</strong> Savara Inc.專注於開發針對美國罕見呼吸疾病的治療，作為一家臨牀階段生物製藥公司，市值約為 13 億美元。</p>
<p>Savara 在一系列監管活動中，正準備通過 MOLBREEVI 增強其市場地位，該藥物目前正在接受 FDA 的優先審查，修訂後的 PDUFA 日期定於 2026 年 11 月。此延期是 Savara 對 FDA 請求的全面回應的結果，強調了其在滿足監管標準方面的承諾，沒有任何安全或有效性方面的擔憂。該公司的戰略舉措還包括在賓夕法尼亞州獲得新的總部租約，並通過多場高端醫學會議保持強勁的參與。這些步驟反映了 Savara 在應對複雜審批流程和擴大運營足跡方面的積極態度，這對於在競爭激烈的生物技術領域實現規模化至關重要。</p>
<ul>
<li>點擊這裏深入瞭解 Savara 的完整分析健康報告。</li>
<li>通過我們的過去報告獲取 Savara 的歷史趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 4 月的 SVRA 收入和支出明細</p>
<h2>Klaviyo (KVYO)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Klaviyo, Inc.提供基於雲的軟件即服務平台，覆蓋包括美國、美國、亞太地區、英國、歐洲、中東和非洲在內的多個地區，市值約為 59.3 億美元。</p>
<p><strong>運營：</strong> Klaviyo 運營一個基於雲的 SaaS 平台，主要通過其互聯網軟件部門產生收入，該部門貢獻了 12.3 億美元。</p>
<p>Klaviyo 在追求創新的過程中，最近加深了與 Canva 和 Shopify 的整合，增強了營銷人員設計和執行針對性活動的能力。這一合作至關重要，因為它利用了 Klaviyo 強大的數據分析能力，預計年收入增長為 16.2%，盈利預計將激增 81.7%。此外，該公司在研發方面的戰略重點顯而易見，進行了大量投資，旨在發展其營銷自動化工具——這一舉措不僅與行業向更靈活、數據驅動的營銷解決方案的轉變相一致，還顯著提升了其在高風險科技領域的競爭優勢。</p>
<ul>
<li>點擊這裏通過我們的綜合健康報告深入瞭解 Klaviyo 的複雜性。</li>
<li>通過查看我們的過去表現報告獲取 Klaviyo 的歷史表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth"/></p>
<p>KVYO 截至 2026 年 4 月的收益和收入增長</p>
<h2>利用機會</h2>
<ul>
<li>點擊這裏訪問我們完整的 67 只美國高增長科技和人工智能股票指數。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時瞭解您股票的任何重要更新。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>對其他可能性感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

KVYO

SVRA

GYRE

<p>美國市場在過去一年中上漲了 30%，預計年收益將增長 16%。關鍵的高增長科技股包括 Gyre Therapeutics、Savara 和 Klaviyo，這些公司均展現出強勁的收入和盈利增長。Gyre 專注於器官纖維化治療，Savara 專注於罕見呼吸疾病，而 Klaviyo 提供基於雲的 SaaS 平台。這些公司在競爭激烈的市場環境中具備強勁的增長潛力，顯著的創新和戰略舉措增強了它們的市場存在感</p>

<p>The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities.</p>
<div class="lb-trans"><p>美國市場在過去一週保持平穩，但在過去 12 個月中上漲了 30%，預計年收益增長將達到 16%。在這種強勁的增長潛力背景下，識別高增長科技股需要關注那些展現出強大創新能力和適應能力的公司，以便抓住新興機會。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.35%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.05%</td>
<td>27.75%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>34.05%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>54.35%</td>
<td>95.02%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.25%</td>
<td>46.50%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.35%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.05%</td>
<td>27.75%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>34.05%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>54.35%</td>
<td>95.02%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.25%</td>
<td>46.50%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 67 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>Gyre Therapeutics (GYRE)</h2>
<div class="lb-trans"><h2>Gyre Therapeutics (GYRE)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $679.38 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制藥公司，專注於開發和商業化用於治療器官纖維化的小分子藥物，市值為 6.7938 億美元。</p>
</div><p><strong>Operations:</strong> Gyre Therapeutics focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily from its pharmaceuticals segment, which reported $116.59 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Gyre Therapeutics 專注於開發和商業化針對器官纖維化的小分子藥物，主要通過其製藥部門產生收入，該部門報告收入為 1.1659 億美元。</p>
</div><p>Gyre Therapeutics, despite a challenging year with a 58.4% decline in earnings, remains a beacon of innovation within the biotech sector. The company's revenue growth forecast at 20.5% annually surpasses the US market average of 11%, reflecting strong underlying business dynamics. Recently, Gyre has made significant strides in regulatory advancements; its lead product candidate Hydronidone received priority review status in China for treating chronic hepatitis B-induced liver fibrosis, highlighting its potential impact on global health outcomes. Moreover, Gyre's strategic merger with Cullgen aims to enhance its research capabilities and market reach, promising robust future growth prospects amidst competitive pressures and fluctuating profit margins.</p>
<div class="lb-trans"><p>儘管 Gyre Therapeutics 經歷了一個充滿挑戰的年份，盈利下降 58.4%，但它仍然是生物技術領域創新的燈塔。該公司的收入增長預計為每年 20.5%，超過美國市場平均水平 11%，反映出強勁的基本商業動態。最近，Gyre 在監管進展方面取得了重大進展；其主要產品候選 Hydronidone 在中國獲得了優先審查狀態，用於治療慢性乙型肝炎引起的肝纖維化，突顯其對全球健康結果的潛在影響。此外，Gyre 與 Cullgen 的戰略合併旨在增強其研究能力和市場覆蓋，承諾在競爭壓力和利潤波動中實現強勁的未來增長前景。</p>
</div><ul>
<li>Get an in-depth perspective on Gyre Therapeutics' performance by reading our health report here.</li>
<li>Examine Gyre Therapeutics' past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的健康報告，深入瞭解 Gyre Therapeutics 的表現。</li>
<li>查看 Gyre Therapeutics 的過去表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/revenue-and-expenses-breakdown"/></p>
<p>GYRE Revenue and Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 GYRE 收入和支出明細</p>
</div><h2>Savara (SVRA)</h2>
<div class="lb-trans"><h2>Savara (SVRA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Savara Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare respiratory diseases in the United States, with a market cap of $1.30 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Savara Inc.是一家臨牀階段生物製藥公司，致力於開發針對美國罕見呼吸疾病的治療，市值為 13 億美元。</p>
</div><p><strong>Operations:</strong> Savara Inc. is focused on developing treatments for rare respiratory diseases in the U.S., operating as a clinical-stage biopharmaceutical company with a market cap of approximately $1.30 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> Savara Inc.專注於開發針對美國罕見呼吸疾病的治療，作為一家臨牀階段生物製藥公司，市值約為 13 億美元。</p>
</div><p>Savara, amidst a flurry of regulatory activities, is poised to enhance its market position with MOLBREEVI for autoimmune PAP, now under Priority Review by the FDA with a revised PDUFA date set for November 2026. This extension follows Savara's comprehensive response to the FDA's requests, underscoring its commitment to meeting regulatory standards without any noted concerns on safety or efficacy. The company’s strategic maneuvers also include securing a new headquarters lease in Pennsylvania and maintaining robust engagement through multiple high-profile medical conferences. These steps reflect Savara’s proactive approach in navigating complex approval processes and expanding its operational footprint, essential for scaling up in the competitive biotech landscape.</p>
<div class="lb-trans"><p>Savara 在一系列監管活動中，正準備通過 MOLBREEVI 增強其市場地位，該藥物目前正在接受 FDA 的優先審查，修訂後的 PDUFA 日期定於 2026 年 11 月。此延期是 Savara 對 FDA 請求的全面回應的結果，強調了其在滿足監管標準方面的承諾，沒有任何安全或有效性方面的擔憂。該公司的戰略舉措還包括在賓夕法尼亞州獲得新的總部租約，並通過多場高端醫學會議保持強勁的參與。這些步驟反映了 Savara 在應對複雜審批流程和擴大運營足跡方面的積極態度，這對於在競爭激烈的生物技術領域實現規模化至關重要。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Savara.</li>
<li>Gain insights into Savara's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Savara 的完整分析健康報告。</li>
<li>通過我們的過去報告獲取 Savara 的歷史趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>SVRA Revenue and Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 SVRA 收入和支出明細</p>
</div><h2>Klaviyo (KVYO)</h2>
<div class="lb-trans"><h2>Klaviyo (KVYO)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Klaviyo, Inc. offers a cloud-based software-as-a-service platform across various regions including the United States, the Americas, Asia-Pacific, the United Kingdom, Europe, the Middle East, and Africa with a market cap of approximately $5.93 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Klaviyo, Inc.提供基於雲的軟件即服務平台，覆蓋包括美國、美國、亞太地區、英國、歐洲、中東和非洲在內的多個地區，市值約為 59.3 億美元。</p>
</div><p><strong>Operations:</strong> Klaviyo operates a cloud-based SaaS platform, generating revenue primarily from its Internet Software segment, which contributed $1.23 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> Klaviyo 運營一個基於雲的 SaaS 平台，主要通過其互聯網軟件部門產生收入，該部門貢獻了 12.3 億美元。</p>
</div><p>Klaviyo, in its pursuit of innovation, has recently deepened its integration with Canva and Shopify, enhancing marketers' ability to design and execute targeted campaigns efficiently. This collaboration is pivotal as it leverages Klaviyo's robust data analytics capabilities, evidenced by a 16.2% annual revenue growth forecast and an impressive expected earnings surge of 81.7% per year. Additionally, the company's strategic focus on R&amp;D is clear with substantial investments aimed at evolving their marketing automation tools—a move that not only aligns with industry shifts towards more agile, data-driven marketing solutions but also significantly boosts their competitive edge in the high-stakes tech landscape.</p>
<div class="lb-trans"><p>Klaviyo 在追求創新的過程中，最近加深了與 Canva 和 Shopify 的整合，增強了營銷人員設計和執行針對性活動的能力。這一合作至關重要，因為它利用了 Klaviyo 強大的數據分析能力，預計年收入增長為 16.2%，盈利預計將激增 81.7%。此外，該公司在研發方面的戰略重點顯而易見，進行了大量投資，旨在發展其營銷自動化工具——這一舉措不僅與行業向更靈活、數據驅動的營銷解決方案的轉變相一致，還顯著提升了其在高風險科技領域的競爭優勢。</p>
</div><ul>
<li>Navigate through the intricacies of Klaviyo with our comprehensive health report here.</li>
<li>Gain insights into Klaviyo's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的綜合健康報告深入瞭解 Klaviyo 的複雜性。</li>
<li>通過查看我們的過去表現報告獲取 Klaviyo 的歷史表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/fb58748b-3872-42d2-b2b9-f2de2937c914/chart/earnings-and-revenue-growth"/></p>
<p>KVYO Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>KVYO 截至 2026 年 4 月的收益和收入增長</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Click here to access our complete index of 67 US High Growth Tech and AI Stocks.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 67 只美國高增長科技和人工智能股票指數。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時瞭解您股票的任何重要更新。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

值得關注的美國高增長科技股